Page 1

EQUASENS Technology for a more human experience PRESS RELEASE Strong H1 2026 business performance : H1 revenue of € 124.5 million ( + 7.3 % on a reported basis ) and ARR of € 111.1 million at 30 June 2026 ( + 8.8 % vs. 30 June 2025 ) • • • Strong growth in maintenance and subscriptions revenue ( + 8.4 % to € 55.7 million ) , including solid organic growth ( + 4.7 % ) in H1 2026 Positive momentum in the French Pharmacy business , driven in particular by software innovations and services ( + 4.3 % in H1 2026 ) , and in Italy , supported by growth in the customer base and new hardware solutions ( + 42.4 % in H1 2026 ) Successful launch of the new digital training offering ( virtual classrooms ) introduced by the MEDICAL SOLUTIONS Division Villers - lès - Nancy , 30 July 2026 , 6:00 p.m. CEST - Equasens ( ISIN : FR0012882389 – Ticker : EQS ) , a leader in digital healthcare solutions , today reported H1 revenue of € 124.5 million , up 7.3 % on a reported basis and 1.4 % like - for - like . Group revenue 2025 at 30/06/2026 ( € m ) 2026 Reported Reported basis basis Change / Reported basis Of which external growth Of which Ségur Wave 2 Like - for - like change ( organic growth ) Q1 57.1 61.4 4.4 7.7 % 2.5 0.2 1.7 2.9 % Q2 58.9 63.0 4.1 6.9 % 3.8 0.4 0.0 % Total 116.0 124.5 8.5 7.3 % 6.3 0.6 1.7 1.4 % Revenue includes a € 6.3 million contribution from changes in scope relating to EREVO ( MEDICAL SOLUTIONS Division ) , NOVAPROVE and the acquisition of the DIS business ( AXIGATE LINK Division ) . Revenue recognised under Wave 2 of the Ségur digital health programme amounted to € 0.6 million in H1 ( AXIGATE LINK Division ) . The R & D and services teams across the Group's business Divisions are focused on developing new functionalities to further enhance customers ' software solutions . Revenue generated under the Ségur Wave 2 programme , which do not arise from the ordinary course of business , are excluded from like - for - like comparisons . 1/6